Chris Wood, a prominent Asia equity strategist at Jefferies, has reduced Alibaba's weight in his Asia ex-Japan...
Chris Wood, a prominent Asia equity strategist at Jefferies, has reduced Alibaba's weight in his Asia ex-Japan long-only portfolio by one percentage point to increase exposure to South Korean memory chipmakers Samsung Electronics and SK Hynix.
BABA has already moved down -25% over the recent 30-90 day window.
signal brief
Chris Wood, a prominent Asia equity strategist at Jefferies, has reduced Alibaba's weight in his Asia ex-Japan long-only portfolio by one percentage point to increase exposure to South Korean memory chipmakers Samsung Electronics and SK Hynix. In his June 28, 2026 newsletter, Wood describes the AI build-out as 'the most dramatic capex cycle' and argues that falling token costs will drive rising DRAM prices (Jevons Paradox), making memory suppliers the core beneficiaries. The rotation underscores a shift in institutional capital away from Chinese tech names like Alibaba toward AI hardware plays. While the cut is modest (1pp), Wood's explicit rationale—funding the 'mother of all cycles'—signals a potential broader reallocation theme. The move is based on a single source (Economic Times article) and represents a portfolio manager's tactical shift rather than a fundamental change at Alibaba. However, if replicated by other funds, it could weigh on BABA's near-term sentiment. Source: Economic Times.
evidence
- https://economictimes.indiatimes.com/markets/stocks/news/funding-the-mother-of-all-cycles-chris-wood-cuts-indian-stocks-to-double-down-on-south-korean-chip-giants/articleshow/132045664.cmsweb
- https://www1.hkexnews.hk/search/titlesearch.xhtml?app=annpubgemccaprev&search_text=&stock_id=09988&from_date=20260625&to_date=20260625web
- https://www1.hkexnews.hk/search/titlesearch.xhtml?app=annpubgemccaprev&search_text=&stock_id=09988&from_date=20260626&to_date=20260626web
- https://data.sec.gov/api/xbrl/companyfacts/CIK0001577552.jsonedgar
- https://www.alibabagroup.com/en/ir/homeweb
Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.